Hashimoto Noboru, Ito Shizuka, Harazono Akira, Tsuchida Akiko, Mouri Yasuhiro, Yamamoto Akihito, Okajima Tetsuya, Ohmi Yuhsuke, Furukawa Keiko, Kudo Yasusei, Kawasaki Nana, Furukawa Koichi
Biochemistry II, Nagoya University Graduate School of Medicine, Nagoya 466-0065, Japan.
Tissue Regeneration, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8504, Japan.
iScience. 2024 Oct 11;27(11):111139. doi: 10.1016/j.isci.2024.111139. eCollection 2024 Nov 15.
Siglec-7, an inhibitory receptor expressed on natural killer (NK) cells, recognizes sialic acid-containing glycans. However, the ligand glycan structures of Siglec-7 and its carrier proteins have not been comprehensively investigated. Here, we identified four sialyltransferases that are used for the synthesis of ligand glycans of Siglec-7 and two ligand O-glycan-carrier proteins, PODXL and MUC13, using a colon cancer line. Upon binding of these ligand glycans, Siglec-7-expressing immune cells showed reduced cytotoxic activity, whereas cancer cells expressing ligand glycans underwent signal activation, leading to enhanced invasion activity. To clarify the structure of the ligand glycan, podoplanin (PDPN) identified as a Siglec-7 ligand-carrier protein, was transfected into HEK293T cells using sialyltransferase cDNAs. Mass spectrometry of the products revealed a ligand glycan, tri-sialylated T antigen. These results indicate that Siglec-7 interaction with its ligand generates bidirectional signals in NK and cancer cells, leading to the efficient escape of cancers from host immune surveillance.
唾液酸结合免疫球蛋白样凝集素7(Siglec-7)是一种在自然杀伤(NK)细胞上表达的抑制性受体,可识别含唾液酸的聚糖。然而,Siglec-7的配体聚糖结构及其载体蛋白尚未得到全面研究。在此,我们利用一种结肠癌细胞系鉴定出了四种用于合成Siglec-7配体聚糖的唾液酸转移酶以及两种配体O-聚糖载体蛋白,即血小板内皮细胞黏附分子(PODXL)和黏蛋白13(MUC13)。这些配体聚糖结合后,表达Siglec-7的免疫细胞显示出细胞毒性活性降低,而表达配体聚糖的癌细胞则经历信号激活,导致侵袭活性增强。为了阐明配体聚糖的结构,将被鉴定为Siglec-7配体载体蛋白的血小板反应蛋白1(PDPN)利用唾液酸转移酶cDNA转染到293T人胚肾细胞中。对产物进行质谱分析,揭示了一种配体聚糖,即三唾液酸化T抗原。这些结果表明,Siglec-7与其配体的相互作用在NK细胞和癌细胞中产生双向信号,导致癌症能够有效地逃避宿主免疫监视。